Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.

Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, Yamazaki H, Eimoto T, Ueda R.

Cancer Lett. 2007 Oct 18;256(1):112-9. Epub 2007 Jul 19.

PMID:
17658213
2.

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR.

Clin Cancer Res. 2004 Oct 15;10(20):6956-61.

3.

cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.

Sève P, Mackey JR, Isaac S, Trédan O, Souquet PJ, Pérol M, Cass C, Dumontet C.

Lung Cancer. 2005 Sep;49(3):363-70.

PMID:
15923058
5.

Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.

De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F.

J Thorac Oncol. 2011 Apr;6(4):768-73. doi: 10.1097/JTO.0b013e31820d7818.

6.

Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.

Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y, Miyagi Y.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S558-64. doi: 10.1245/s10434-011-2054-z. Epub 2011 Sep 13.

PMID:
21913012
7.

Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients.

Wu F, Zhang J, Hu N, Wang H, Xu T, Liu Y, Zheng Y.

Cancer Epidemiol. 2014 Dec;38(6):728-32. doi: 10.1016/j.canep.2014.08.008. Epub 2014 Sep 20.

PMID:
25246379
9.

Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.

Kobayashi H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T.

Ann Surg. 2012 Aug;256(2):288-96. doi: 10.1097/SLA.0b013e3182536a42.

PMID:
22580938
10.

Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.

Mori R, Ishikawa T, Ichikawa Y, Taniguchi K, Matsuyama R, Ueda M, Fujii Y, Endo I, Togo S, Danenberg PV, Shimada H.

Oncol Rep. 2007 May;17(5):1201-5.

PMID:
17390066
11.

The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.

Matsumura N, Nakamura Y, Kohjimoto Y, Inagaki T, Nanpo Y, Yasuoka H, Ohashi Y, Hara I.

BJU Int. 2011 Jul;108(2 Pt 2):E110-6. doi: 10.1111/j.1464-410X.2010.09932.x. Epub 2010 Dec 16.

12.

Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.

Xiao JC, Zhang TP, Zhao YP.

Hepatogastroenterology. 2013 Mar-Apr;60(122):258-62. doi: 10.5754/hge12687.

PMID:
23574652
13.

Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.

Pérez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M, Mazo A.

Biochem Pharmacol. 2008 Aug 1;76(3):322-9. doi: 10.1016/j.bcp.2008.05.011. Epub 2008 May 20.

PMID:
18589402
14.

Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.

Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M.

Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.

15.

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.

Borbath I, Verbrugghe L, Lai R, Gigot JF, Humblet Y, Piessevaux H, Sempoux C.

Eur J Cancer. 2012 May;48(7):990-6. doi: 10.1016/j.ejca.2011.11.006. Epub 2011 Dec 1.

PMID:
22137164
16.

Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.

Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, Danesi R, de Braud F.

Pharmacogenomics J. 2010 Jun;10(3):180-90. doi: 10.1038/tpj.2009.53. Epub 2009 Nov 10.

PMID:
19901957
17.

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G.

Curr Cancer Drug Targets. 2011 Jan;11(1):123-9. Review.

PMID:
20578980
18.

Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples.

Hubeek I, Giovannetti E, Broekhuizen AJ, Pastor-Anglada M, Kaspers GJ, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):787-93. doi: 10.1080/15257770802145942.

PMID:
18600541
19.

Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.

Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, Lin CC, Huang TC, Yang PC, Yang CH.

Lung Cancer. 2008 Dec;62(3):334-43. doi: 10.1016/j.lungcan.2008.03.010. Epub 2008 May 2.

PMID:
18450322
20.

Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.

Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sueda T.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S646-55. doi: 10.1245/s10434-011-2140-2. Epub 2011 Nov 16.

PMID:
22086444

Supplemental Content

Support Center